BioMarin Pharmaceutical


Want a discount? Become a member by purchasing Annual Subscription!
SKU: BMRN Category:


BioMarin Pharmaceutical Inc. delivered a mixed set of results for the previous quarter, with revenues well below analyst expectations but managed earnings beat. The company celebrates a robust 15% total revenue growth in the third quarter, propelled by the success of Voxzogo, slated to become the company’s inaugural blockbuster product. It has also transformed into a flourishing, fully integrated industry powerhouse in biotechnology, boasting annual revenues poised to surpass $2.4 billion this year, with an anticipated ascent to nearly $3 billion in the coming year. The company’s global footprint has expanded significantly, evolving from a US-centric operation with 300 employees to a worldwide presence in almost 80 countries, employing over 3,000 individuals. The recent milestones achieved with the introduction of Voxzogo and Roctavian mark a pivotal juncture, making it reasonable to pass the baton to the next leader. With expanded age approvals and increased manufacturing commitments, Voxzogo’s outlook is optimistic. The Roctavian journey, while facing challenges in healthcare system integration, maintains momentum with over 100 patients tested globally. In summary, the future appears bright, a testament to the collective effort and collaboration that has defined the company’s journey.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!